Table: Eisai -2024/25 parent results
May 15 (Reuters)-
Eisai Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2025 Mar 31, 2024 Mar 31, 2026 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 376.40 367.41
(+2.4 pct) (+2.1 pct)
Operating 34.61 23.04
(+50.2 pct)
Recurring 35.04 24.48
(+43.1 pct)
Net 41.60 20.31
(+104.8 pct) (-33.5 pct)
EPS 146.72 yen 70.82 yen
Ann Div 160.00 yen 160.00 yen 160.00 yen
-Q2 Div 80.00 yen 80.00 yen 80.00 yen
-Q4 Div 80.00 yen 80.00 yen 80.00 yen
NOTE - Eisai Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China